ARO-APOC3
- Generic Name
- ARO-APOC3
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
ARO-APOC3 is an investigational RNAi therapeutic targeting apolipoprotein C-III (APOC3). It received an Orphan Drug designation by the FDA for the treatment of familial chylomicronemia syndrome.
- Associated Conditions
- -
- Associated Therapies
- -
Study of ARO-APOC3 in Adults With Dyslipidemia
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 418
- Registration Number
- NCT05413135
- Locations
- 🇺🇸
Westside Medical Associates of Los Angeles, Beverly Hills, California, United States
🇺🇸Valley Clinical Trials; Inc., Northridge, California, United States
🇺🇸Desert Medical Group, Inc., Palm Springs, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath